套細胞淋巴瘤治療市場規模、佔有率和成長分析：按類型、作用機制、給藥途徑、最終用戶和地區分類－2026-2033年產業預測

2024 年全球套細胞淋巴瘤治療市場價值為 24.1 億美元，預計到 2025 年將成長至 26.1 億美元，到 2033 年將成長至 48.9 億美元，在預測期（2026-2033 年）內複合年成長率為 8.2%。

套細胞淋巴瘤治療市場正顯著擴張，這主要受此B細胞癌症發生率上升以及對更有效治療方案的迫切需求所驅動。近年來，治療格局已從傳統的化療免疫療法轉向包括定向小分子藥物、抗體藥物複合體（ADC）和細胞療法等先進療法。這一轉變至關重要，因為生存率仍然有限，導致對更有效替代療法的需求日益成長。Ibrutinib的問世標誌著治療結果的轉捩點，隨後創新療法的批准使市場更加多元化。標靶治療的日益普及以及對成本效益的日益關注預計將推動市場滲透，尤其是在歐洲和亞洲，這些地區人口老化迫切需要新的癌症治療方案。

全球套細胞淋巴瘤治療市場的成長要素

分子和影像技術的進步顯著提高了套細胞淋巴瘤的早期檢出率，使醫療專業人員能夠在疾病早期階段啟動標靶治療。這種精準診斷最大限度地減少了治療抗藥性，改善了患者預後，促使臨床醫生優先考慮創新療法。因此，對特效藥的需求不斷成長，推動了研發投入，並擴大了其在全球醫療體系中的市場佔有率。此外，人們對診斷準確性的信心增強，也加速了保險覆蓋範圍的擴大，使患者更容易獲得新的有效治療方案。

全球套細胞淋巴瘤治療市場的限制因素

套細胞淋巴瘤的治療費用高昂，尤其是創新標靶治療和聯合治療，給醫療預算和患者都帶來了沉重的經濟負擔。保險公司通常會設定嚴格的報銷標準，限制特定病患小組獲得最有效藥物的機會。這種對成本的敏感性會阻礙預算敏感型市場快速接受新療法，迫使醫療服務提供者選擇價格較低但療效較差的替代療法，可能抑制財政資源有限地區的市場成長。此外，頻繁的後續觀察也顯著增加了整體治療成本。

全球套細胞淋巴瘤治療藥物市場趨勢

全球套細胞淋巴瘤治療市場正經歷著向精準免疫療法的顯著轉變，這主要得益於新一代CAR-T細胞療法和雙特異性抗體等創新療法的引入。這些標靶治療針對腫瘤特異性抗原，在提高療效的同時，最大限度地減少了對健康組織的損傷。隨著臨床合作的深入以及以患者為中心的臨床試驗所提供的可靠真實世界數據的積累，醫療系統已積極響應，將資源重新分配到專業的輸液中心，並加強了培訓項目。這項策略性投資增強了醫生的信心，促進了這些療法在大學醫院和社區癌症中心的廣泛應用，並為治療領域創造了永續的發展勢頭。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球套細胞淋巴瘤治療市場規模：依類型分類

• 聯合治療
  • 聯合治療化療
  • 聯合治療標靶治療
  • 聯合治療
• 單藥治療
  • 化療
  • 標靶治療（單藥治療）
  • 免疫療法（單藥療法）

全球套細胞淋巴瘤治療藥物市場規模：依作用機轉分類

• 布魯頓蛋白酪氨酸激酶（BTK）抑制劑
• 烷化劑
• DNA合成抑制劑
• 微管抑制劑
• 單株抗體
• 其他

全球套細胞淋巴瘤治療藥物市場規模：依給藥途徑分類

• 口服
• 腸外

全球套細胞淋巴瘤治療市場規模：依最終用戶分類

• 醫院
• 研究機構
• 其他

全球套細胞淋巴瘤治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• AstraZeneca PLC
• AbbVie Inc.
• BeiGene Ltd.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson（Janssen）
• Novartis AG
• Celgene Corporation
• Eli Lilly and Company
• Gilead Sciences Inc.
• Pharmacyclics LLC
• Sunesis Pharmaceuticals Inc.
• Kymera Therapeutics Inc.
• Fate Therapeutics Inc.
• Actinium Pharmaceuticals Inc.
• Nurix Therapeutics Inc.
• VelosBio Inc.
• Morphosys AG
• Innate Pharma SA

結論與建議

Global Mantle Cell Lymphoma Therapeutics Market size was valued at USD 2.41 Billion in 2024 and is poised to grow from USD 2.61 Billion in 2025 to USD 4.89 Billion by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).

The mantle cell lymphoma therapeutics market is expanding significantly, driven by the rising incidence of this B-cell cancer alongside an unmet medical need for more effective treatments. Over the years, the landscape has evolved from traditional chemo-immunotherapy to include advanced options such as targeted small molecules, antibody-drug conjugates, and cellular therapies. This shift is critical as survival rates remain limited, prompting demand for better alternatives. The introduction of ibrutinib marked a turning point in treatment outcomes, while subsequent approvals of innovative therapies have diversified the market. The growing adoption of these targeted therapies and the increasing focus on cost-effectiveness will likely enhance market penetration, particularly as aging populations in Europe and Asia demand novel solutions in oncology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Mantle Cell Lymphoma Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Mantle Cell Lymphoma Therapeutics Market Segments Analysis

Global mantle cell lymphoma therapeutics market is segmented by type, mechanism of action, route of administration, end user and region. Based on type, the market is segmented into combination therapy and monotherapy. Based on mechanism of action, the market is segmented into Bruton tyrosine kinase (BTK) inhibitors, alkylating agents, DNA synthesis inhibitors, microtubule inhibitors, monoclonal antibodies and others. Based on route of administration, the market is segmented into oral and parenteral. Based on end user, the market is segmented into hospitals, research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Mantle Cell Lymphoma Therapeutics Market

Advancements in molecular and imaging technologies have significantly enhanced the early detection of mantle cell lymphoma, enabling healthcare professionals to initiate targeted therapies during less advanced stages of the disease. This precision in diagnosing the condition minimizes treatment resistance, leading to improved patient outcomes, which prompts clinicians to favor innovative therapeutics. Consequently, there is a growing demand for specialized pharmaceutical products, driving investment in research and expanding market presence within healthcare systems worldwide. Additionally, heightened confidence in diagnostic precision encourages broader insurance coverage, further facilitating patient access to new and effective treatment options.

Restraints in the Global Mantle Cell Lymphoma Therapeutics Market

The elevated expenses associated with mantle cell lymphoma therapeutics, particularly for innovative targeted treatments and combination therapies, create significant financial burdens on both healthcare budgets and patients. Insurers frequently impose stringent criteria for reimbursement, limiting access to the most effective medications for specific patient groups. This cost sensitivity can hinder rapid adoption in markets that are budget-conscious, prompting healthcare providers to opt for more affordable, yet less effective alternatives, which can stifle market growth in regions with constrained financial resources. Furthermore, the requirement for frequent follow-up appointments substantially adds to the overall treatment costs.

Market Trends of the Global Mantle Cell Lymphoma Therapeutics Market

The Global Mantle Cell Lymphoma Therapeutics market is witnessing a significant shift towards precision immunotherapy, driven by the introduction of innovative treatments such as next-generation CAR-T cells and bispecific antibodies. These targeted therapies focus on tumor-specific antigens, leading to improved efficacy while minimizing damage to healthy tissues. As clinical collaborations deepened and patient-centric trials generated robust real-world evidence, healthcare systems adapted by reallocating resources to specialized infusion centers and enhancing training programs. This strategic investment fosters physician confidence and stimulates broad adoption across both academic and community oncology settings, creating a sustainable momentum in the therapeutic landscape.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Mantle Cell Lymphoma Therapeutics Market Size by Type & CAGR (2026-2033)

• Market Overview
• Combination Therapy
  • Chemotherapy Combinations
  • Targeted Therapy Combinations
  • Immunotherapy Combinations
• Monotherapy
  • Single-Agent Chemotherapy
  • Targeted Therapy Monotherapy
  • Immunotherapy Monotherapy

Global Mantle Cell Lymphoma Therapeutics Market Size by Mechanism of Action & CAGR (2026-2033)

• Market Overview
• Bruton Tyrosine Kinase (BTK) Inhibitors
• Alkylating Agents
• DNA Synthesis Inhibitors
• Microtubule Inhibitors
• Monoclonal Antibodies
• Others

Global Mantle Cell Lymphoma Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Parenteral

Global Mantle Cell Lymphoma Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Research Institutes
• Others

Global Mantle Cell Lymphoma Therapeutics Market Size & CAGR (2026-2033)

• North America (Type, Mechanism of Action, Route of Administration, End User)
  • US
  • Canada
• Europe (Type, Mechanism of Action, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Mechanism of Action, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Mechanism of Action, Route of Administration, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Mechanism of Action, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Janssen)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmacyclics LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sunesis Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kymera Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fate Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Actinium Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nurix Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VelosBio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Morphosys AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innate Pharma SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations